Nathan Lipsett
Riverdale, GANPI 1487628509
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by GSK at 27.4% of the total. Reporting peaked in 2019 at $1,865 and has fallen 96.6% since, to $63 in 2023.
Across 341 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$942
- Mylan Specialty L.p.$459
- Sanofi$214
- Grifols USA, LLC$191
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,264100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 104 | $1,716 |
| AstraZeneca | 60 | $1,181 |
| Boehringer Ingelheim | 52 | $942 |
| Mylan Specialty L.p. | 21 | $459 |
| Sanofi | 10 | $214 |
| Grifols USA, LLC | 11 | $191 |
| Regeneron Healthcare Solutions, Inc. | 7 | $159 |
| United Therapeutics Corporation | 8 | $154 |
| Actelion Pharmaceuticals US, Inc. | 8 | $147 |
| Novartis | 9 | $130 |
| Amgen | 5 | $112 |
| Insmed, Inc. | 5 | $87 |
| Genentech USA, Inc. | 5 | $83 |
| Circassia Inc. | 5 | $83 |
| Mallinckrodt Enterprises LLC | 3 | $77 |
| Philips North America LLC | 4 | $69 |
| Baxter Healthcare | 3 | $66 |
| Kaleo, Inc. | 2 | $47 |
| Shire North American Group Inc | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Optinose US, Inc. | 2 | $34 |
| Pfizer | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Inari Medical, Inc. | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Electromed, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$247
- FASENRA$125
- Yupelri$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.